US 12,463,463 B2
Bispecific antibodies and uses thereof
Yue Liu, Hayward, CA (US); Wenyan Cai, Hayward, CA (US); Jiadong Shi, Hayward, CA (US); and Zhejun Jia, Hayward, CA (US)
Assigned to Ab Therapeutics, Inc., Hayward, CA (US)
Appl. No. 17/425,830
Filed by Ab Therapeutics, Inc., Hayward, CA (US)
PCT Filed Jan. 28, 2020, PCT No. PCT/US2020/015311
§ 371(c)(1), (2) Date Jul. 26, 2021,
PCT Pub. No. WO2020/159918, PCT Pub. Date Aug. 6, 2020.
Claims priority of provisional application 62/797,818, filed on Jan. 28, 2019.
Prior Publication US 2022/0169728 A1, Jun. 2, 2022
Int. Cl. A61P 35/00 (2006.01); C07K 16/28 (2006.01); H02J 50/10 (2016.01); H04B 5/79 (2024.01); H04R 25/00 (2006.01); A61K 39/00 (2006.01)
CPC H02J 50/10 (2016.02) [A61P 35/00 (2018.01); C07K 16/2809 (2013.01); C07K 16/2827 (2013.01); C07K 16/2887 (2013.01); C07K 16/2896 (2013.01); H04B 5/79 (2024.01); H04R 25/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/56 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); H04R 2225/31 (2013.01)] 12 Claims
 
1. An antibody or antigen-binding fragment thereof that binds to CD3 and CD20 comprising:
a first heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3; and
a first light chain variable region (VL) comprising CDRs 1, 2, and 3;
a second heavy chain variable region (VH) comprising CDRs, 1, 2, and 3; and
a second light chain variable region (VL) comprising CDRs, 1, 2, and 3;
wherein the first VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 22-24, respectively;
the second VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 16-18, respectively; and
the first and second VL CDRs 1, 2, 3 amino acid sequences are set forth in
 
 (SEQ ID NO: 71)
 
 RASSSVSYIX1,
 
 
 
 (SEQ ID NO: 29)
 
 ATSNLAS,
 
 and
 
 
 
 (SEQ ID NO: 72)
 
 X2QWTSX3PX4T,
respectively,
wherein (a) X1 is Leu, Pro, Ala, Gly, Glu, Thr, Val, Asp, or Ser, X2 is Gln, X3 is Asn, and X4 is Pro;
(b) X1 is His, X2 is Met, X3 is Asn, and X4 is Pro;
(c) X1 is His, X2 is Gln, X3 is Ser, Thr, or Val, and X4 is Pro; or
(d) X1 is His, X2 is Gln, X3 is Asn, and X4 is Val or Ala.